On February 21, 2025, Roche announced a new sequencing platform called Sequencing by Expansion, or SBX. This technology promises a faster and more adaptable approach to next generation sequencing and could represent an important advance for both research and clinical applications.

The method works by turning target DNA or RNA into a much longer structure known as an Xpandomer. This stretching effect improves signal clarity and reduces background noise. As a result, scientists can carry out highly accurate single molecule sequencing using a CMOS based sensor. The outcome is sequencing that is quicker, more flexible and easier to scale, whether the need is a handful of samples or thousands.

Matt Sause, CEO of Roche Diagnostics, explained that SBX was designed to solve long standing problems with sequencing. He emphasized that the speed and efficiency of this system could change the way genomics is used in medicine and research. According to Roche, the process can cut turnaround time from sample to data from several days to just a few hours, which may be particularly valuable in patient care settings where rapid results are critical.

The origins of SBX can be traced back to Stratos Genomics, founded by Mark Kokoris and Robert McRuer. Roche acquired the company in 2020 and has since integrated the technology into its broader portfolio, which also includes the KAPA line of library preparation tools.

The company believes this innovation could have wide impact across genetics, oncology, immunology and neurodegenerative research, with eventual applications in clinical diagnostics. SBX may become one of the most important developments in sequencing technology in recent years, opening doors to faster insights and more personalized care.